Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Activity of 3BNC117 and 10-1074 Combination in HIV-infected Individuals
NCT02825797Phase 1Completed
- Sponsor
- The Rockefeller University
- Start
- Jun 2016
- Primary completion
- Aug 2018
- Modality
- Anti-infectious Disease mAbs
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of Teropavimab and zinlirvimab in human immunodeficiency virus type 1 infection (HIV-1) (7 arms), sponsored by The Rockefeller University. Primary endpoints: Number of participants with adverse events, Decline in plasma HIV-1 RNA levels and 2 more. Started Jun 2016; status: completed.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02825797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02825797.